Screener
Crinetics Pharmaceuticals CRNX Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total current liabilities | 71,086 | 85,072 |
| Operating lease liabilities, non-current | 41,319 | 42,052 |
| Deferred revenue, non-current | 3,346 | 3,810 |
| Other liabilities | 4,926 | 3,240 |
| TOTAL LIABILITIES | 120,677 | 134,174 |
| Commitments and contingencies (Note 6) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding at March 31, 2026 or December 31, 2025 | — | — |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's other non-current liabilities?
- Crinetics Pharmaceuticals (CRNX) reported other non-current liabilities of $4.93M in Q1 2026.
- How has Crinetics Pharmaceuticals's other non-current liabilities changed year-over-year?
- Crinetics Pharmaceuticals's other non-current liabilities increased by 178.8% year-over-year, from $1.77M to $4.93M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Crinetics Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude